Market Overview

Morgan Stanley Sees Execution Priced In For Becton, Dickinson and Co.

Share:
Related BDX
Earnings Scheduled For February 2, 2017
7 Biotech And Healthcare Picks For 2017 From Cantor Fitzgerald
Supreme Court declines to review Retractable Tech's litigation against BD, case remanded to Texas district court for redetermination of damages; BD up 1% (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Becton, Dickinson and Co. (NYSE: BDX).

In the report, Morgan Stanley noted, “Recent meetings stressed confidence in ~5% sales growth and greater leverage in FY15. BD continues to express interest in larger deals, though <$1B is more likely in our view. Inversions are possible but limited targets suggest less probable. At 17x CY15 EPS, execution is priced in; remain EW.”

Becton, Dickinson and Co. closed on Monday at $118.30.

Latest Ratings for BDX

DateFirmActionFromTo
Jan 2017Raymond JamesDowngradesStrong BuyOutperform
Jan 2017JP MorganDowngradesOverweightNeutral
Sep 2016CitigroupDowngradesNeutralSell

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BDX)

View Comments and Join the Discussion!